{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-22-000099","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2022-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.664429+00:00","generated_at":"2026-06-24T08:47:37.491148+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Praxis CMO Bernard Ravina to step down, become part-time strategic advisor","bullets":["Bernard Ravina, Chief Medical Officer, transitions to part-time strategic advisor effective Aug 1, 2022.","Cash payment of $373,688 paid over consulting period ending May 1, 2023.","Outstanding equity awards will continue to vest during consulting period subject to service.","Health benefits continuation provided during consulting period; payment subject to signing release.","Ravina resigns from all officer and director positions with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-22-000099","json":"https://secwatch.observer/filing/0001689548-22-000099.json","markdown":"https://secwatch.observer/filing/0001689548-22-000099.md","text":"https://secwatch.observer/filing/0001689548-22-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/0001689548-22-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/prax-20220721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:47:37.491148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9de4e683b6","claim":"Bernard Ravina changed role as Chief Medical Officer at Praxis Precision Medicines, Inc..","evidence_excerpt":"On July 21, 2022, Bernard Ravina, Chief Medical Officer of Praxis Precision Medicines, Inc. (the “ Company ”), who is currently on leave attending to family medical matters, and the Company mutually decided that Dr. Ravina will transition from his full-time position as Chief Medical Officer to a part-time role as strategic advisor to the Company on August 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/0001689548-22-000099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}